Print this page
Radiation
-
A Phase 3, Randomized, Open-Label Study of MK-5684 (004) Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Nextgeneration Hormonal Agent (NHA).
Protocol: 082307Principal Investigator:
- Biren Saraiya
Applicable Disease Sites: Prostate -
A Phase 3, Randomized, Open-Label Study of MK-5684 (004) Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Nextgeneration Hormonal Agent (NHA).
Protocol: 082307Principal Investigator:
- Biren Saraiya
Applicable Disease Sites: Prostate -
An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer.
Protocol: 082401Principal Investigator:
- Biren Saraiya
Applicable Disease Sites: Urinary Bladder -
An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer.
Protocol: 082401Principal Investigator:
- Biren Saraiya
Applicable Disease Sites: Urinary Bladder -
The Phase III 'High Five Trial' Five Fraction Radiation for High-Risk Prostate Cancer.
Protocol: 082413Principal Investigator:
- Lara Hathout
Applicable Disease Sites: Prostate -
The Phase III 'High Five Trial' Five Fraction Radiation for High-Risk Prostate Cancer.
Protocol: 082413Principal Investigator:
- Lara Hathout
Applicable Disease Sites: Prostate -
A032201: Short TeRm Intensified Pembrolizumab (KEytruda) and Tivozanib for High-risk renal cell carcinoma STRIKE
Protocol: 082502Principal Investigator:
- Biren Saraiya
Applicable Disease Sites: Kidney -
A032201: Short TeRm Intensified Pembrolizumab (KEytruda) and Tivozanib for High-risk renal cell carcinoma STRIKE
Protocol: 082502Principal Investigator:
- Biren Saraiya
Applicable Disease Sites: Kidney -
A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of
Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients
With Advanced Clear Cell Renal Cell Carcinoma
Protocol: 082510Principal Investigator:
- Biren Saraiya
Applicable Disease Sites: Kidney -
A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of
Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients
With Advanced Clear Cell Renal Cell Carcinoma
Protocol: 082510Principal Investigator:
- Biren Saraiya
Applicable Disease Sites: Kidney -
Phase III Double-Blinded Trial of Immune-Based Therapy with a Live Biotherapeutic MO-03 or Placebo for Frontline Therapy of Advanced Clear Cell Renal Cell Carcinoma.
Protocol: 082608Principal Investigator:
- Biren Saraiya
Applicable Disease Sites: Kidney -
Phase III Double-Blinded Trial of Immune-Based Therapy with a Live Biotherapeutic MO-03 or Placebo for Frontline Therapy of Advanced Clear Cell Renal Cell Carcinoma.
Protocol: 082608Principal Investigator:
- Biren Saraiya
Applicable Disease Sites: Kidney -
A Phase I Study to Evaluate the Safety of Naltrexone and Propranolol in Combination with Standard of Care Ipilimumab and Nivolumab in Patients with Advanced Melanoma.
Protocol: 092302Principal Investigator:
- Sarah Weiss
Applicable Disease Sites: Melanoma, Skin -
A Phase I Study to Evaluate the Safety of Naltrexone and Propranolol in Combination with Standard of Care Ipilimumab and Nivolumab in Patients with Advanced Melanoma.
Protocol: 092302Principal Investigator:
- Sarah Weiss
Applicable Disease Sites: Melanoma, Skin -
A Phase 1b Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO).
Protocol: 092305Principal Investigator:
- Sarah Weiss
Applicable Disease Sites: Melanoma, Skin -
A Phase 1b Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO).
Protocol: 092305Principal Investigator:
- Sarah Weiss
Applicable Disease Sites: Melanoma, Skin